| Therapeutic | Lunsekimig2 |
| Target 1 | TSLP |
| Heavy Chain 1 | EVQLVESGGGVVQPGGSLRLSCAASGSGFGVNILYWYRQAAGIERELIASITSGGITNYVDSVKGRFTISRDNSENTMYLQMNSLRAEDTGLYYCASRNIFDGTTEWGQGTLVTVSS |
| Light Chain 1 | na |
| 100% seqID Fv 1 Structure | None |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | ALB |
| Heavy Chain 2 | EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS |
| Light Chain 2 | na |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | 8oi2 [Fvs: B] |
| 95-98% seqID Structure [Fv 2] | 8oi2 [Fvs: B] |
| There are no identical PDB matches to at least one Fv in this therapeutic. Click the links to build models with ABodyBuilder2: [Fv 1] [Fv 2] |
Non-identical sequences have been numbered using the Chothia scheme and aligned to Lunsekimig2.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.
Heavy chain
| Position | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 52A | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 82A | 82B | 82C | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| lunsekimig2_Fv2 | E | V | Q | L | V | E | S | G | G | G | V | V | Q | P | G | G | S | L | R | L | S | C | A | A | S | G | F | T | F | R | S | F | G | M | S | W | V | R | Q | A | P | G | K | G | P | E | W | V | S | S | I | S | G | S | G | S | D | T | L | Y | A | D | S | V | K | G | R | F | T | I | S | R | D | N | S | K | N | T | L | Y | L | Q | M | N | S | L | R | P | E | D | T | A | L | Y | Y | C | T | I | G | G | S | L | S | R | S | S | Q | G | T | L | V | T | V | S | S |
| 8oi2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | G | S | L | R | L | S | C | A | A | S | G | F | T | F | R | S | F | G | M | S | W | V | R | Q | A | P | G | K | E | P | E | W | V | S | S | I | S | G | S | G | S | D | T | L | Y | A | D | S | V | K | G | R | F | T | I | S | R | D | N | A | K | T | T | L | Y | L | Q | M | N | S | L | K | P | E | D | T | A | V | Y | Y | C | T | I | G | G | S | L | S | R | S | S | Q | G | T | Q | V | T | V | S | S |
Follow these links to our prediction tools:
| Format | Trispecific and Pentavalent (sc-5-VH); Bispecific entry |
| Isotype | na;na |
| Highest Clinical Trial (Feb '25) | Phase-II |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2023 |
| INN Year Recommended | 2024 |
| Companies Involved | Sanofi |
| Conditions Approved | na |
| Conditions Active | Asthma, Inflammation |
| Conditions Discontinued | na |
| Notes | Pentavalent; targets two different epitopes on IL13 and TSLP. Fv3 Chimeric: Llama/Human |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
